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Abstract
Introduction Various perinatal factors, including birth weight,
birth order, maternal age, gestational age, twin status, and
parental smoking, have been postulated to affect breast cancer
risk in daughters by altering the hormonal environment of the
developing fetal mammary glands. Despite ample biologic
plausibility, epidemiologic studies to date have yielded
conflicting results. We investigated the associations between
perinatal factors and subsequent breast cancer risk through
meta-analyses.
Methods We reviewed breast cancer studies published from
January 1966 to February 2007 that included data on birth
weight, birth order, maternal age, gestational age, twin status,
and maternal or paternal smoking. Meta-analyses using random
effect models were employed to summarize the results.
Results We found that heavier birth weights were associated
with increased breast cancer risk, with studies involving five
categories of birth weight identifying odds ratios (ORs) of 1.24
(95% confidence interval [CI] 1.04 to 1.48) for 4,000 g or more
and 1.15 (95% CI 1.04 to 1.26) for 3,500 g to 3,999 g, relative
to a birth weight of 2,500 to 2,599 g. These studies provided no
support for a J-shaped relationship of birthweight to risk.
Support for an association with birthweight was also derived
from studies based on three birth weight categories (OR 1.15
[95% CI 1.01 to 1.31] for ≥4,000 g relative to <3,000 g) and
two birth weight categories (OR 1.09 [95% CI 1.02 to 1.18] for
≥3,000 g relative to <3,000 g). Women born to older mothers
and twins were also at some increased risk, but the results were
heterogeneous across studies and publication years. Birth
order, prematurity, and maternal smoking were unrelated to
breast cancer risk.
Conclusion Our findings provide some support for the
hypothesis that in utero exposures reflective of higher
endogenous hormone levels could affect risk for development of
breast cancer in adulthood.
Introduction
Intrauterine environmental exposures to endogenous or exog-
enous hormones, notably estrogens, may influence the subse-
quent development of breast cancer in offspring [1]. During
pregnancy, levels of circulating estrogens and other hormones
with growth-enhancing properties are at least 10 times higher
than those in nonpregnant women, with increases seen with
advancing gestational age [2-4]. The hypothesis that breast
cancer in daughters may be influenced by the intrauterine envi-
ronment is receiving increased attention [5]. Perinatal factors,
including birth weight, birth order, maternal age, gestational
age, twin status, and parental smoking, have been postulated
as risk factors for breast cancer through altered hormonal influ-
ences on the developing fetal mammary glands [1]. Despite
ample biologic plausibility, this hypothesis is difficult to evalu-
ate directly [5], and previous epidemiologic studies have
reported conflicting results [6,7].
Here we review the epidemiologic studies that have assessed
the association between perinatal factors and breast cancer
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risk in daughters. A meta-analytical approach was applied in
order to clarify further the possible role played by the intrauter-
ine environment in the etiology of breast cancer.
Materials and methods
Identification of studies
The data retrieved for the systematic review were based on
searches of all published papers, letters, abstracts, and review
articles on birth weight, birth order, maternal age, gestational
age, twin status, and maternal or paternal smoking and breast
cancer using the MEDLINE database from January 1966
through February 2007. We used keywords combining text
words, with terms for six perinatal factors combined with terms
for breast cancer (Table 1). We also manually searched the
reference lists of all studies that fulfilled the inclusion criteria
for further relevant publications. Articles were included in our
systematic review if they fulfilled the following three criteria:
the exposure status of at least one of six perinatal risk factors
of interest was compared with nonexposure status; the out-
come focused on the daughter's breast cancer morbidity or
mortality using an epidemiologic study design (case-control
design, data linkage study, or cohort study design); and the
article was written in English language. We excluded animal
studies, investigations focusing on male breast cancer,
reviews, and studies that did not provide separate relative risks
for breast cancer. We also excluded studies if odds ratios
(ORs) or relative risks (RRs) were not specifically provided,
raw data were not available for calculation of risks, or the
emphasis of analyses was on hazard ratios or standardized
incidence ratios.
Statistical analyses
For the purposes of meta-analysis, birth weight was classified
in three different ways: five categories (<2,500 g, 2,500 to
2,999 g [referent], 3,000 to 3,499 g, 3,500 to 3,999 g, and
≥4,000 g); three categories (<3,000 g [referent], 3,001 to
3,999 g, and ≥4,000 g); and two categories (<3,000 g [or
≤3,000 g; referent] and ≥3,000 g [or >3,000 g]). Birth order
was examined using two different categorical schemes: 1 (ref-
erent) versus ≥2; and 1 (referent), 2 to 4, and ≥5. Maternal age
was classified into three categories: <25 years old (referent),
25 to 29 years old, and ≥30 years old. Gestational age was
also analyzed in two ways: ≤36 weeks versus ≥37 weeks (ref-
erent); and ≤32 weeks versus ≥33 weeks (referent). To exam-
ine twin status, three classification schemes were employed:
twin versus singleton (referent); monozygotic twin (or sister
twins if zygosity was not reported) versus singleton (referent);
and dizygotic twin (or sister-brother twins if zygosity was not
reported) versus singleton (referent). Maternal or paternal
smoking was considered as follows: no smoking during preg-
nancy (referent) versus smoking during pregnancy. If the crite-
ria utilized in an article were slightly different from our criteria,
then we included the data and described the difference in a
footnote.
ORs and 95% confidence intervals (CIs) were recalculated
from published frequency tables of individual studies using the
Mantel-Haenszel common OR estimate. However, the
reported OR (95% CI) was used when the published studies
did not provide further details as to the frequencies of the
exposure variables. If the manuscript reported the results after
performing a stratified analysis, then we re-calculated the
crude OR by combining across strata. A random-effects
model was used to obtain summary ORs and 95% CIs.
Heterogeneity was assessed by heterogeneity test using
Cochran Q statistics [8]. Publication bias was assessed
according to the Egger regression asymmetry test, and the
Begg and Mazumdar adjusted rank correlation tests [9,10].
The Egger test is a simple linear regression of the natural log
of ORs or RRs against its precision (the inverse of its standard
error) [10]. The Begg and Mazumdar rank correlation test
reports the rank correlation (Kendall's tau) between the stand-
ardized effect size and the standard errors of these effects. If
asymmetry is caused by publication bias, then we would
expect that high standard errors (small studies) would be
associated with larger effect sizes (ORs or RRs) or low stand-
ard errors (large studies) would be associated with smaller
effect sizes [9]. The Begg and Mazumdar test makes fewer
assumptions than does the Egger test, but it is insensitive to
many types of bias (lower power) that the Egger test is sensi-
tive to [11].
When significant heterogeneity or publication bias was found,
we performed subgroup analyses by study design (case-con-
trol study versus cohort study), and the source of information
(data linkage versus self-report) to assess the impact on
between-study variations (heterogeneity). Many of the large-
scale studies, especially cohort studies, were published after
2000; thus, we classified publication years into before 2000
versus 2000 or later in order to assess publication biases
associated with small study sizes. Few studies focused on
either Asians or African-Americans, and so it was not possible
to examine ethnicity effects. All statistical analyses were con-
ducted using STATA (Version 8.2 [special edition]; Stata
Corp., College Station, TX, USA).
Results
We identified 34 studies that assessed the association
between birth weight and breast cancer risk (Table 2): 19
case-control studies (eight population based, three nested, six
record linkage based, and two twin-based) and 15 cohort
studies (seven population based and eight record linkage
based). Many studies showed positive association between
heavier birth weight and breast cancer risk [12-31], and some
of the studies observed stronger effects among younger (<45
years) or premenopausal women [14,22,29,30]. In contrast,
studies observing no association [32-41] or a negative one
[42-45] also have been reported. Additionally, some authors
reported a J-shaped relationship between birth weight andAvailable online http://breast-cancer-research.com/content/10/1/R8
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breast cancer risk [12,14,15,18,25,33,35,37,45], particularly
for early-onset cancers [18].
Among 34 studies of birth weight and breast cancer, we
selected studies that employed the same categories of birth
weight. To evaluate whether a J-shaped relationship existed,
we grouped birth weight into more than three categories. The
findings of meta-analysis of eight studies that utilized five cat-
egories of birth weight (<2,500, 2,500 to 2,999, 3,000 to
3,499, 3,500 to 3,999, and ≥4,000 g) and 11 studies that
used three categories (<3,000, 3,000 to 3,999, and ≥4,000
g) are shown in Figures 1 and 2. To include more studies, we
also categorized birthweights as <3,000 g (or ≤3,000 g) and
≥3,000 g (or >3,000 g; Figure 3). Sixteen studies among all
34 studies were included in the meta-analyses for birth weight
and breast cancer: seven studies [13,14,18,32,33,35,44]
were included in the all three meta-analyses; four studies
[22,23,27,39] were included in the two of the three meta-anal-
yses; and five studies were included in only one meta-analysis
[12,16,28,34,38]. There was no significant heterogeneity
across studies (P_Q test > 0.05 for all categories). In the five-
category meta-analysis, ORs were 1.11 (95% CI 0.90 to 1.33)
for birth weight <2,500 g, 1.11 (0.99 to 1.25) for 3,000 to
3,499 g, 1.15 (1.04 to 1.26) for 3,500 to 3,999 g, and 1.24
(1.04 to 1.48) for ≥4,000 g relative to the referent category of
2,500 to 2,999 g. In the three-category meta-analysis, ORs
were 1.06 (95% CI 0.98 to 1.14) for 3,000 to 3,999 g and
1.15 (1.01 to 1.31) for ≥4,000 g relative to the referent cate-
gory of <3,000 g. In the two-category meta-analysis, ORs
were 1.09 (95% CI 1.02 to 1.18) for the category of >3,000
g (or ≥3,000 g) relative to the referent category of ≤3,000 g
(or <3,000 g).
We identified 17 studies (15 case-control and two cohort) that
assessed the association between birth order and breast can-
cer risk (Table 3). Eight of the studies reported an inverse rela-
tionship [14,20,31,35,36,42,46,47]. Some studies found
significantly lower risks for second or later born children ver-
sus first-born children [31,46]. Some studies found signifi-
cantly or marginally significantly reduced risk among women
Figure 1
Meta-analysis of the association between birth weight (five categories) and risk for breast cancer Meta-analysis of the association between birth weight (five categories) and risk for breast cancer. The tests for homogeneity and for publication bias 
in the studies analyzed are as follows. Category I (birth weight <2,500 g) versus reference: Q = 9.66 (8 degrees of freedom), P = 0.29; Begg test, 
P = 0.75; Egger test, P = 0.66. Category II (2,500 to 2,999 g) is the reference. Category III (3,000 to 3,499 g) versus reference: Q = 6.53 (8 
degrees of freedom), P = 0.59; Begg test, P = 0.25; Egger test, P = 0.46. Category IV (3,500 to 3,999 g) versus reference: Q = 4.17 (8 degrees 
of freedom), P = 0.84; Begg test, P = 0.60; Egger test, P = 0.93. Category V (≥4,000 g) versus reference: Q = 11.18 (8 degrees of freedom), P = 
0.19; Begg test, P = 0.25; Egger test, P = 0.30. 1We used adjusted odds ratios (ORs) for meta-analysis because the numbers of cases and con-
trols were not represented in the original article. CI, confidence interval.Breast Cancer Research    Vol 10 No 1    Park et al.
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whose birth had been preceded by the birth of at least five sib-
lings [20,35]. Other several studies noted an increased risk
associated with higher birth order [15,37,48,49], whereas
some studies failed to observe such an association
[12,18,32,50]. One study did not supply the estimated risk but
describe the P value by the mean difference of birth order [51].
For the meta-analysis, we included 14 studies (13 case-con-
trol studies and one cohort) that used two birth order catego-
ries: 1 (referent) and ≥2. There was significant heterogeneity
across all studies (P_Q test < 0.01), although there was no
significant heterogeneity across the case-control studies
(P_Q test = 0.90). As shown in Figure 4, there was no differ-
ence in risk according to birth order across all studies (OR
0.97 [95% CI 0.91 to 1.04]) or within the case control studies
(OR 0.99 [95% CI 0.94 to 1.04]). We calculated the crude
odds ratio from the cohort study [31], and the result was very
different from the summary OR (calculated crude OR 0.28
[95% CI 0.21 to 0.36]). The results of all case-control studies
were near null, whereas the cohort study found a significant
risk reduction in birth orders of 2 or greater. We also examined
the seven studies that classified individuals according to three
birth order levels (1 [referent], 2 to 4, ≥5; Figure. 4). There was
significant heterogeneity across studies (all of which were
case-control studies) for the highest birth order category (P_Q
test = 0.03) Women with a birth order of ≥5 were at nonsig-
nificantly reduced risk compared with first-born women (OR
0.88 [95% CI 0.75–1.01]). There was no difference in risk for
women of birth orders 2 to 4 (OR 0.97 [95% CI 0.91–1.03]).
We identified 28 studies (22 case-control and six cohort) that
assessed the association between maternal age and breast
cancer risk (Table 4). Seven studies observed modestly
increased risks for daughters born to older mothers
[15,31,32,36,42,46,52]. A pattern of slight decrease after
modest increase in risk was found in five other studies [50,53-
56]. Fourteen studies, however, no association was observed
[12,14,18,20,35,37,38,47,49,57-60]. Two studies did not
estimate the risks [51,61].
In our meta-analyses, we included the 18 studies that reported
categorical data and examined three age categories (≤24 [ref-
Figure 2
Meta-analysis of the association between birth weight (three categories) and risk for breast cancer Meta-analysis of the association between birth weight (three categories) and risk for breast cancer. The tests for homogeneity and for publication 
bias in the studies analyzed are as follows. Category I (birth weight 3,000 to 3,999 g) versus reference (<3,000 g): Q = 4.97 (11 degrees of free-
dom), P = 0.93; Begg test, P = 0.54; Egger test, P = 0.27. Category II (≥4,000 g) versus reference: Q = 13.44 (11 degrees of freedom), P = 0.27; 
Begg test, P = 0.54; Egger test, P = 0.53. CI, confidence interval; OR, odds ratio.Available online http://breast-cancer-research.com/content/10/1/R8
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erent], 25 to 29, and ≥30 years; Figure 5). There was,
however, significant study heterogeneity (P_Q test < 0.01 for
25 to 29 years and for ≥30 years). Heterogeneity was also
present across case-control studies and studies published
after 2000 (P_Q test < 0.01). The ORs (95% CI) were 1.18
(1.05 to 1.11) for 25 to 29 years and 1.23 (1.07 to 1.15) for
≥30 years across all studies.
We identified 15 studies (10 case-control and five cohort) that
assessed the association between prematurity and breast
cancer risk (Table 5). Most studies did not observe a signifi-
cant relationship [13-16,20,25,29,31,33,40,42,45]. Two
studies found that extreme prematurity was associated with an
increased risk (OR 3.96 [95% CI 1.46 to 10.81] for ≤32
weeks relative to ≥33 weeks [32], and SIR (standardized inci-
dence ratio) 6.7 [95% CI 1.4 to 19.5] for <31 weeks [62]). In
contrast, another study [34] found that longer gestation was
associated with a significantly increased risk (OR 8.4 [95% CI
1.3 to 54.4] for ≥40 weeks relative to ≤32 weeks).
There was no significant heterogeneity across studies (P-Q
test = 0.55), whereas we found no association between pre-
maturity (≤36 weeks) and risk (OR 1.04 [95% CI 0.92 to
1.18]; Figure 6). However, a strong publication bias was
observed (P-Egger test = 0.03 and P-Begg test = 0.11;
Figure 7). A significant publication bias occurred because
three studies with smaller standard errors of log RR
[15,16,34] reported RRs near 1.0, whereas five studies with
larger standard errors [13,20,31,33,45] reported substantially
reduced RRs. When the analysis was performed for extreme
prematurity (≤32 weeks), heterogeneity was also evident
across the studies (P-Q test = 0.04), and the association was
not significant (OR 1.20 [95% CI 0.74 to 1.95]).
We examined 13 studies (eight case-control and five cohort)
that assessed the association between twin status and risk
(Table 6). Most studies identified a slightly increased risk
among twins [15,31,32,43,45,58,63-66], with five studies
demonstrating significant associations [31,58,64-66]. In con-
trast, some studies observed a slightly reduced risk
[14,20,67], with one of the risks being marginally significant
[67]. Seven studies [20,32,58,63,65,66] had information on
zygosity. Of these studies, two [58,63] used the twins' sex as
a proxy for zygosity. For monozygotic twins, a reduction in risk
was significant in one study [68]. Most studies failed to
observe an association [20,32,58,63,65,66]. Three studies
reported a significantly increased risk associated with being a
dizygotic twin [58,65,66], whereas other studies reported no
association [20,32,63,67] (Figure 8).
The Q test for heterogeneity was not significant (P-Q test =
0.13), and the meta-analysis of 13 studies examining twin sta-
tus (without regard to zygosity) found an OR of 1.22 (95% CI
1.01 to 1.11). There was no evidence of any publication bias
(P-Egger test or P-Begg test >0.1). There were little evidence
of heterogeneity (P-Q test > 0.1 for monozygotic or dizygotic
twins), and breast cancer risk was not significantly increased
among either monozygotic (OR 0.95 [95% CI 0.85 to 1.07])
or dizygotic (OR 1.17 [95% CI 0.99 to 1.37]) twins, albeit
based on limited statistical power. In subgroup analysis by
study design, cohort studies identified significantly increased
risk (OR 1.23 [95% CI 1.00 to 1.11]) for breast cancer in
twins versus singletons, with no study heterogeneity (P-Q test
= 0.07). Case-control studies showed no association with
twin status (OR 1.39 [95% CI 0.91 to 1.12]). There was no
evidence of any publication bias (P-Egger test or P-Begg test
> 0.05) among the case-control or cohort studies. In subgroup
analysis by study design and zygosity, there were no heteroge-
neity in studies (P-Q test > 0.1). In subgroup analysis by study
year, significant heterogeneity by publication year was identi-
fied (P = 0.01), and the OR (95% CI) for studies published
before 2000 was 1.06 (0.97 to 1.47), whereas the OR (95%
CI) for studies published in 2000 or later was 1.27 (1.03 to
1.58).
Figure 3
Meta-analysis of the association between birth weight (two categories)  and risk for breast cancer Meta-analysis of the association between birth weight (two categories) 
and risk for breast cancer. The tests for homogeneity and for publica-
tion bias in the studies analyzed are as folows. Reference (<3,000 g [or 
≤3,000 g]) versus ≥3,000 g (or >3,000 g): Q = 11.57 (15 degrees of 
freedom), P = 0.93; Begg test, P = 0.15; Egger test, P = 0.50. CI, con-
fidence interval; OR, odds ratio.Breast Cancer Research    Vol 10 No 1    Park et al.
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We identified nine studies that assessed the association
between maternal or paternal smoking and risk (Table 7). Two
cohort studies reported nonsignificantly reduced risks associ-
ated with maternal smoking (OR 0.49 [95% CI 0.29 to 1.03]
[68]; OR 0.8 [95% CI 0.5 to 1.1] [31]), whereas a case-con-
trol study [43] identified a significant positive association (age-
adjusted OR 2.7 [95% CI 1.1 to 6.3]), although its crude OR
was not statistically significant (OR 1.1 [95% CI 0.7 to 1.7]).
The majority of studies, however, identified no associations
with maternal [14,20,33,35,58,69] or paternal [20,35,69]
smoking during pregnancy.
There was no heterogeneity or publication bias (P-Q test >
0.05, P-Egger test and P-Begg test > 0.1 among all studies,
case-control or cohort). The meta-analysis for maternal smok-
ing (Figure 9) found no significant association with risk (OR
0.98 [95% CI 0.86 to 1.13]), although cohort studies [40,68]
noted a significant negative association with maternal smoking
(OR 0.59 [95% CI 0.41 to 0.85]).
Discussion
The main finding of our meta-analysis was that heavier birth
weight was associated with increased breast cancer risk
(18% increased risk for the heaviest weight). Twin status was
associated with 1.2-fold higher risk for breast cancer relative
to a singleton birth. Although we found some evidence of
increased risk associated with older maternal age (OR 1.16
for maternal age ≥30 years), there were heterogeneous find-
ings across study designs.
Figure 4
Meta-analysis of the association between birth order and risk for breast cancer Meta-analysis of the association between birth order and risk for breast cancer. The tests for homogeneity and for publication bias in the studies ana-
lyzed are as follows. Category I (birth order 2+) versus reference (birth order 1): Q = 87.79 (13 degrees of freedom), P < 0.01; Begg test, P = 0.44; 
Egger test, P = 0.46. Category II (birth order 5+ and 2 to 4) versus reference: Q = 4.56 (6 degrees of freedom), P = 0.60; Begg test, P = 0.37; 
Egger test, P = 0.44. Category II (birth order ≥6, 2 to 5) versus reference: Q = 14.42 (6 degrees of freedom), P = 0.60; Begg test, P = 0.37; Egger 
test, P = 0.44. 1Category I of birth order was 2+ vs 1. 2Category II of birth order was composed of two conditions: 5+ and 2 to 4; and ≥6 and 2 to 
5 vs 1. 3We used adjusted odds ratios (ORs) for meta-analysis because the numbers of cases and controls were not represented in the original arti-
cle. CI, confidence interval.Available online http://breast-cancer-research.com/content/10/1/R8
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Most studies identified an increased risk for breast cancer with
heavier birth weight, with the association being particularly
strong for premenopausal or early-onset breast cancers
[14,22,29,30]. Our result was similar to the findings of a
recent meta-analysis of 26 studies, which revealed that high
birth weight was associated with a RR of 1.23 and restricted
to premenopausal women (OR 1.25 [95% CI 1.14 to 1.38)
[70]. This analysis grouped birth weight into two categories
(classified into high and low birth weight in each study, regard-
less of specific weight in terms of grams), preventing
evaluation of dose-response relationships. We did in fact
observe evidence of a dose-response relationship of risk with
birth weight, although this was based on a relatively small
number of studies involving three or four categories.
Although some studies identified a J-shaped relationship
between birth weight and breast cancer risk
[12,14,15,18,25,33,35,37,45], others failed to note an
increased risk associated with very low birth weights. A recent
study involving 3,066 breast cancer patients and 106,504
comparison individuals in a Danish cohort also found no ele-
vated risk among those with very low birth weights [71]. Simi-
larly, our meta-analysis provided little evidence of increased
risk for very low birth weights.
Although the mechanisms underlying the association between
high birth weight and breast cancer risk remain unclear, it has
been suggested that heavier birth weights may result from
increased  in utero exposuresto factors such as insulin-like
growth factor-I or estrogens [72-76]. These substances may
act as mitogens by increasing the likelihood of genetic muta-
tions [75,77]. However, several studies have failed to find any
correlation between umbilical cord estrogen levels and birth
weight [78,79]. One study, however, reported a significant
positive relationship with estriol [80]. Further studies should
be undertaken to assist in the resolution of these conflicting
data.
Our analysis found no association of breast cancer risk with
birth orders between 2 and 4, but we did note a somewhat
reduced risk associated with higher birth orders (at least 5),
although the results were heterogeneous across studies. Bio-
logically, pregnancy estrogen levels appear to be higher dur-
ing first pregnancies and decline in successive pregnancies
[81]. Furthermore, cord blood levels of estradiol, estrone, and
progesterone are lower for later born than first born children
[82]. These findings suggest that the reduced risk associated
with higher birth orders may relate to lower estrogen levels.
However, evidence supporting birth order as a risk factor for
breast cancer is limited, with further investigations needed to
evaluate dose-response relationships more fully.
In our meta-analysis, we found some evidence that having
been born to an older mother was associated with higher
breast cancer risk, although the results were heterogeneous
across studies. Our data failed to support the previous studies
that suggested a J-shaped relationship between maternal age
and breast cancer risk. It was previously suggested that older
maternal age may have an adverse effect on the primordial
mammary gland of their daughters because of altered hormo-
nal profiles [37] or may linked to the epigenetic change of
mtDNA which can lead to breast carcinogenesis by oocyte
inheritance [83]. However, the two studies that examined
pregnancy estrogen levels according to maternal age found
that both total estrogen and estradiol levels were lowest in
youngest mothers (<20 years of age), highest in those aged
20 to 24 years, and intermediate in mothers over 25 years of
age [78,81]. Thus, it remains unclear from both our meta-anal-
ysis as well as from biologic data whether maternal age is a
proxy for estrogen or estradiol exposure to fetus. Although it
has been suggested that older paternal age may cause germ
cell mutations, previous epidemiologic studies have failed to
support an association [35,20,69,82,84,85]. Because the
Figure 5
Meta-analysis for the association between maternal age and the risk of  breast cancer Meta-analysis for the association between maternal age and the risk of 
breast cancer. The tests for homogeneity and for publication bias in the 
studies analyzed are as follows. Maternal age 25 to 29 years: Q = 
39.40 (17 degrees of freedom), P < 0.01; Begg test, P = 0.85; Egger 
test, P = 0.38, Maternal age 30+ years: Q = 67.34 (17 degrees of 
freedom), P < 0.01; Begg test, P = 0.88; Egger test, P = 0.07. 1The 
reference for maternal age is ≤24 years old. CI, confidence interval; 
OR, odds ratio.Breast Cancer Research    Vol 10 No 1    Park et al.
Page 8 of 34
(page number not for citation purposes)
purpose of this study was to evaluate whether the intrauterine
hormone environment affects subsequent breast cancer risk,
our meta-analysis did not include paternal age.
We observed no association between prematurity and breast
cancer risk. Biologically, women having abruptio placentae or
an extremely premature birth (<32 week) have been shown to
have elevated levels of human chorionic gonadotropin and α-
fetoprotein, which could inhibit the differentiation of stem cells
in human breast tissue cells [15]. Gestational age is related to
birth weight, of course, because birth weights in infants born
prematurely are lower than those in infants born at term [13].
Twin pregnancies are associated with an approximate dou-
bling of estrogen levels compared with singleton pregnancies
[86,87]. Dizygotic twin pregnancies have elevated levels of
estrogens and gonadotropins [88-90]. It has therefore been
postulated that twins, especially dizygotic twins, could be at an
elevated risk for breast cancer. In general, our results did not
support differences in risk between monozygotic and dizygotic
twins, and there was evidence that risk estimates published
after 2000 were qualitatively different from those of earlier
studies.
Studies of parental smoking, especially maternal smoking, and
daughter's breast cancer risk have yielded inconsistent
results. Biologically, maternal smoking, rather than paternal
smoking, has a greater impact on the fetus. In the meta-ana-
lytic results, both factors failed to exhibit a significant associa-
tion with risk. Some studies have reported that maternal
smoking in pregnancy reduces serum estrogen levels [91,92].
A recent experimental study reported that both estradiol-17β
levels and progesterone:estradiol-17β ratios were reduced in
pregnant mice exposed to cigarette smoke [93]. However, the
relevance of these findings to humans is unclear.
Figure 6
Meta-analysis of studies assessing the association of prematurity and risk for breast cancer Meta-analysis of studies assessing the association of prematurity and risk for breast cancer. The tests for homogeneity and for publication bias in the 
studies analyzed are as follows. Category 36+: Q = 5.91 (7 degrees of freedom), P = 0.55; Begg test, P = 0.11; Egger test, P = 0.03. Category 
32+: Q = 10.10 (4 degrees of freedom), P = 0.04; Begg test, P = 0.09; Egger test, P = 0.40. 1Category of prematurity (week): ≤36 versus ≥37 (ref-
erence). 2Category of prematurity (week): ≤32 versus ≥33 (reference). CI, confidence interval; OR, odds ratio.
Figure 7
Begg's funnel plot for publication bias in meta-analysis of premature  birth and breast cancer risk Begg's funnel plot for publication bias in meta-analysis of premature 
birth and breast cancer risk. Premature birth (gestational age ≤36 
weeks) was compared with gestational age ≥37 weeks. Egger test, P = 
0.03; Begg test, P = 0.11. rr, relative risk; s.e., standard error.Available online http://breast-cancer-research.com/content/10/1/R8
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These meta-analyses are based on results from studies involv-
ing heterogeneous designs and methodology. We did note
between-study heterogeneity for the associations of birth
order, maternal age, and twin status. To resolve the heteroge-
neous findings, we considered the influence of study design
and the date of study publication on the results by subgroup
analyses. However, heterogeneity in studies could only be
explained partially.
Effects of maternal age, birth order, prematurity (cut-off value
32 weeks), and maternal smoking were found to be heteroge-
neous across study designs, but birth weight and twinning
were comparable. Self-reported measures of perinatal factors
may be vulnerable to misclassification biases, with differential
or nondifferential effects [94,95]. Because studies based on
data linkage to medical records have a lower chance of mis-
classification bias, we conducted subgroup meta-analyses
stratified by source of information (data linkage versus self-
report) and found no substantial differences in the results.
Although the completeness of records is a critical factor in
evaluating biases in studies based on data linkage, most
papers did not provide details about the completeness of
records. We also conducted subgroup meta-analyses strati-
fied by publication year. Only twin status exhibited significant
heterogeneity according to publication year (<2000 versus
≥2000).
Our findings may be somewhat inflated because of our
dependence on crude rather than adjusted ORs or RRs. A
possible misclassification bias for zygosity might have resulted
in studies that used sex as a proxy for zygosity [96]. Because
this bias would probably attenuate associations, additional
investigations are needed to determine the extent of any true
association of risk with twin status.
Conclusion
It has been hypothesized that certain perinatal factors, includ-
ing birth weight and order, twin pregnancies, prematurity,
maternal age, and smoking, may reflect higher estrogenic envi-
ronments in utero, thereby increasing the subsequent risk of
breast cancer. Findings of an increase in breast cancer risk
among daughters exposed to diethylstilbestrol in utero sup-
Figure 8
Meta-analysis for the association between twinship and risk for breast cancer Meta-analysis for the association between twinship and risk for breast cancer. The tests for homogeneity and for publication bias in the studies ana-
lyzed are as follows. Twinship: Q = 18.79 (13 degrees of freedom), P = 0.13; Begg test, P = 0.78; Egger test, P = 0.24. Monozygote twin: Q = 
5.79 (6 degrees of freedom), P = 0.45; Begg test, P = 0.55; Egger test, P = 0.85. Dizygote twin: Q = 12.53 (6 degrees of freedom), P = 0.06; 
Begg test, P = 1.0; Egger test, P = 0.3. 1The authors used the female twins as the proxy for the monozygote twin and the female twin with male twin 
as the proxy for the dizygote twin. 2Women aged 21 to 45 years. 3Women aged 50 to 64 years. CI, confidence interval; OR, odds ratio.Breast Cancer Research    Vol 10 No 1    Park et al.
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ports this hypothesis [97,98]. Although the current meta-anal-
ysis found evidence that higher birth weights are associated
with increased breast cancer risk, older maternal age and twin
status were less convincingly related, and birth order and pre-
maturity appeared unrelated. Greater birth weights have been
attributed to higher maternal estrogens levels, which could
affect fetal development [72-74] through epigenetic modifica-
tions of breast stem cells [1,99,100]. Although our findings
regarding birth weight support the hypothesis that higher
estrogen exposures in utero may be involved in the subse-
quent development of breast cancer, further biologic data are
needed to elucidate the relationship fully.
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Figure 9
Meta-analysis for the association of maternal smoking during preg- nancy with risk for subsequent breast cancer Meta-analysis for the association of maternal smoking during preg-
nancy with risk for subsequent breast cancer. The tests for homogene-
ity and for publication bias in the studies analyzed are as follows: Q = 
16.90 (9 degrees of freedom), P = 0.06; Begg test, P = 0.59; Egger 
test, P = 0.31. 1Titus-Ernstoff and coworkers [35] classified three cate-
gories: nonparental smoking, paternal or maternal smoking only or both 
parents smoking during pregnancy. The odds ratios (ORs) of father 
smoking on breast cancer risk was almost unity (OR 1.0, 95% confi-
dence intrval [CI] 0.9 to 1.1). Thus, in this study, the mother smoking 
and both parents smoking versus nonparental smoking can be consid-
ered to the maternal smoking versus no maternal smoking. 2Women 
aged 21 to 45 years. 3Women aged 50 to 64 years.Available online http://breast-cancer-research.com/content/10/1/R8
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Table 1
Search terms used in systematic review
Subject Search term
Breast neoplasm Breast neoplasms, subsequent breast neoplasm, breast neoplasm and daughter
Birth weight Cirth weight, birthweight, birth size
Birth order Birth order, birth rank
Maternal age Maternal age, mother's age, parental age
Gestational age Gestational age, preterm, prematurity, abruption placenta, pre-eclampsia, eclampsia
Twinship Twin, twining, multiple births, multiple pregnancy, monozygote twin, dizygote twin,
Parental smoking Maternal smoking, mother's smoking, paternal smoking, father's smoking, parental smoking
Others Prenatal factors, perinatal factors, intrauterine environment, intrauterine factor, In-utero exposureBreast Cancer Research    Vol 10 No 1    Park et al.
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Table 2
Studies assessing the association of birth weight and the risk for breast cancer
Type of 
study
Ref. Year Design Cases Controls
(or cohort)
Country/
place of study
Birthweight (g) OR (95% CI) Comments
Case-
control 
studies
[42] 1988 PCC 153 461 USA 1,162–2,948 Referent Matched analysis; P for 
trend = 0.41
2,949–3,340 0.65 (0.33–1.26)
3,341–4,451 0.76 (0.41–1.43)
[12]a 1992 LCC 458 1,197 Sweden <2,500 1.18 (0.60–2.33) Adjusted for age and birth 
date
2,500–2,999 Referent
3,000–3,499 1.29 (0.90–1.91)
3,500–3,999 1.47 (1.00–2.18)
≥ 4,000 1.23 (0.80–2.00)
[13] 1996 NCC 550 1,478 USA <2,500 0.56 (0.34–0.93) Adjusted for age
2,500–2,999 0.68 (0.47–0.99)
3,000–3,499 0.71 (0.50–0.99)
3,500–3,999 0.85 (0.59–1.22)
≥ 4,000 Referent
[14] 1996 PCC 922 1,194 USA Age 21–45 
years:
Adjusted for age, 
menopausal status, and 
maternal smoking; P for 
trend = 0.06 among both 
groups. The OR (95% CI) 
for birth weight ≥ 4,000 g 
among patients with early-
onset breast cancer (≤ 30 
years old) was 3.3 (1.0–
11.0)
<2,500 1.3 (0.9–2.0)
2,500–2,999 Referent
3,000–3,499 1.3 (1.0–1.7)
3,500–3,999 1.2 (0.8–1.6)
≥ 4,000 1.7 (1.1–2.5)
Age 50–64 
years:
<2,500 0.9 (0.5–1.7)
2,500–2,999 Referent
3,000–3,499 1.1 (0.7–1.7)
3,500–3,999 0.8 (0.4–1.3)
≥ 4,000 0.6 (0.3–1.1)
[32] 1997 NCC 1068 2,027 Sweden <2,500 0.80 (0.50–1.26) Adjusted for maternal age, 
socioeconomic status, 
parity, and pre-eclampsia or 
eclampsia, neonatal 
jaundice, severe prematurity, 
and twinship
2,500–2,999 Referent
3,000–3,499 1.00 (0.79–1.28)
3,500–3,999 0.99 (0.77–1.26)Available online http://breast-cancer-research.com/content/10/1/R8
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≥ 4,000 1.04 (0.77–1.41)
[33] 1998 PCC 510 436 USA <2,500 1.2 (0.7–2.1) Crude ORs
2,500–2,999 Referent
3,000–3,499 1.0 (0.7–1.5)
3,500–3,999 1.0 (0.7–1.5)
≥ 4,000 1.3 (0.7–2.3)
[15] 2000 LCC 484 2,870 USA <1,500 1.59 (0.61–4.11) Crude ORs
1,500–2,499 1.33 (0.94–1.90)
2,500–3,499 Referent
3,500–4,499 1.08 (0.87–1.34)
≥ 4,500 3.29 (1.37–7.92)
[34] 2001 LTCC 87 87 Sweden <1,999 Referent Matched analysis by 
conditional logistic 
regression
2,000–2,499 1.6 (0.6–4.0)
2,599–2,999 2.4 (0.9–6.2)
≥ 3,000 1.6 (0.4–5.6)
(P trend = 0.05)
[43] 2001 LCC 319 768 USA <2,500 1.4 (0.55–3.4) Crude ORs. Higher birth 
weight (≥ 3,500 g) carried a 
marginal significantly higher 
risk for breast cancer (OR 
1.76 [95% CI 0.90–3.35]) 
relative to lower birth weight 
(<3,500 g)
2,500–3,750 Referent
≥ 3,750 0.9 (0.50–1.6)
[16] 2001 LTCC 90 90 Sweden ≤ 2,000 Referent Crude ORs. Study subjects 
were women with opposite-
sexed pair twins
2,001–2,500 3.2 (0.8–12.6)
2,501–3,000 3.5 (1–13)
3,001–3,500 5.8 (1.3–25.7)
≥ 3,501 12.1 (1.1–138.8)
[35] 2002 PCC 2,088 2,187 USA <2,500 1.10 (0.90–1.35) Adjusted for age and 
residential regions (states)
2,500–2,999 0.90 (0.70–1.10)
3,000–3,499 Referent
3,500–3,999 1.07 (0.90–1.30)
4,000–4,499 0.89 (0.70–1.14)
≥ 4,500 1.18 (0.90–1.51)
[44] 2002 PCC 288 350 China <2,500 0.9 (0.4–2.0) Adjusted for age income, 
family history of breast 
cancer in first-degree 
relative, history of 
fibroadenoma, age at 
menarche, parity, and age at 
first live birth.
Table 2 (Continued)
Studies assessing the association of birth weight and the risk for breast cancerBreast Cancer Research    Vol 10 No 1    Park et al.
Page 14 of 34
(page number not for citation purposes)
2,500–2,999 Referent
3,000–3,499 1.1 (0.8–1.6)
3,500–3,999 0.8 (0.4–1.4)
≥ 4,000 0.7 (0.4–1.4)
[17] 2002 LCC 373 1,150 USA <3,090 Referent Adjusted for parity and age 
at first birth. P for trend = 
0.02
3,090–3,410 1.1 (0.8–1.5)
3,420–3,720 1.2 (0.9–1.6)
≥ 3,630 1.4 (1.1–1.9)
[18] 2003 LCC 881 3,423 Denmark <2,500 1.66 (1.00–2.51) Adjusted for mother's marital 
status, maternal age, and 
birth order
2,500–2,999 0.83 (0.60–1.10)
3,000–3,499 Referent
3,500–3,999 0.98 (0.80–1.17)
≥ 4,000 1.25 (1.00–1.55)
[19] 2004 NCC 89 238 Sweden 100 g increase 1.06 (1.00–1.12) Adjusted for gestational age, 
birth year, and maternal 
hypertension/proteinuria
[45] 2004 LCC 2471 9801 USA <1,500 0.64 (0.40–1.11) Adjusted for age and 
maternal age at first birth
1,500–1,999 1.05 (0.70–1.68)
2,000–2,499 1.02 (0.80–1.31)
2,500–3,499 Referent
3,500–3,999 0.97 (0.90–1.08)
4,000–4,499 0.93 (0.80–1.11)
≥ 4,500 0.69 (0.40–1.09)
[36] 2004 PCC 196 167 USA All subjects: Adjusted for age, race and 
sampling fractions, body 
mass index, household 
income, and maternal age. 
Tertiles are race specific 
with cutpoints derived from 
controls. White women: 
<3,062, 3,062–3,458, 
>3,458 g; black women: 
<3,146, 3,146–3,488, 
>3,488 g. Restricted data 
using birth weight measured 
in pounds and ounces and 
participant delivered in a 
medical facility by a 
physician
Lower tertile 1.0 (0.6–1.7)
Central tertile Referent
Upper tertile 0.7 (0.4–1.2)
White, restricted
data:
Lower tertile 1.1 (0.5–2.4)
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Central tertile Referent
Upper tertile 1.4 (0.6–2.0)
[20] 2006 PCC 2,386 2,502 Poland <2,500 Referent Adjusted for: age, 
education, age at menarche, 
menopausal status and age 
at menopause, age at first 
full-term pregnancy, number 
of full-term pregnancies, 
family history of breast 
cancer among first-degree 
relatives, mammography 
screening, and current body 
mass index. Lower birth 
weight (<2,500 g) carries 
greater risk than birth weight 
of 2,500–4,000 g among 
women under 45 years old
2,500–4,000 1.22 (0.92–1.62)
>4,000 1.54 (1.08–2.19)
(p-trend = 0.01)
[37] 2006 PCC 1,166 2,105 USA <2,495 1.19 (0.85–1.66) Adjusted for age (years), 
education (years), race, 
body mass index, history of 
breast benign disease, 
family history of breast 
cancer, lactation (months), 
age at menarche (years), 
age at first full-term 
pregnancy (years), age at 
menopause (years), parity
2,495–3,130 Referent
3,131–3,855 0.97 (0.75–1.25)
>3,855 1.03 (0.74–1.44)
Cohort 
studies
[21] 1999 LCohort 57 152,590 Sweden <2,500 Referent Standardization for sex, age, 
and age-specific incidence 
rate
2,500–3,999 1.3 (0.6–2.4)
4,000–4,499 1.2 (0.0–6.7)
≥ 4,500 1.3 (0.7–2.3)
[22] 2000 Cohort 37 2,221 UK All ages Adjusted for age. P for trend 
= 0.03 among 
premenopausal women
<3,000 Referent
3,000–3,499 1.05 (0.41–2.71)
3,500–3,999 1.76 (0.72–4.33)
≥ 4,000 2.02 (0.59–6.90)
Premenopausal 
ages
<3,000 Referent
3,000–3,499 1.99 (0.40–9.86)
3,500–3,999 3.26 (0.69–15.36)
≥ 4,000 5.65 (0.95–33.84)
[38] 2001 LCohort 177 3,447 Sweden ≤ 2,000 Referent Crude hazard ratios
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2,001–2,500 1.4 (0.6–3.4)
2,501–3,000 1.9 (0.8–4.3)
3,001–3,500 1.5 (0.6–3.5)
≥ 3,501 1.9 (0.7–5.0)
[39] 2001 Cohort 62 1260 Sweden ≤ 3,000 Referent Singleton only; adjusted for 
gestational age and cohort 
membership
3,010–3,349 1.16 (0.47–2.87)
3,350–3,590 1.65 (0.71–3.86)
3,600–3,960 1.58 (0.67–3.72)
≥ 4,000 1.57 (0.67–3.64)
[23] 2003 LCohort 63 5,352 Sweden <3,000 Referent Crude ORs;P for
trend = 0.01
3,000–3,499 1.46 (0.60–3.43)
3,500–3,999 2.09 (0.90–4.85)
≥ 4,000 2.78 (1.10–7.15)
[24] 2003 LCohort 2,334 106,504 Denmark 1,000 g increase 9 (0.02–17)% Adjusted for age and 
calendar period. Additional 
adjustment for parity and 
age at first birth did not 
indicate confounding
[25] 2003 LCohort 39 1483 Sweden 500–1,999 1.14 (0.70–1.85) Standardized incidence ratio 
(expected/observed)
2,000–2,999 0.71 (0.40–1.15)
≥ 3,000 2.55 (1.03–5.25)
[26]a 2004 LCohort 2,074 91,601 Denmark Median of each 
quintile
Adjusted for age and 
calendar period. No change 
in estimates when 
additionally adjusted for 
parity and age at first birth
2.5 Referent
3.0 0.98 (0.85–1.13)
3.4 1.06 (0.93–1.20)
3.6 1.05 (0.87–1.27)
4.0 1.17 (1.02–1.33)
[27] 2004 Cohort 59 2,176 UK <3,000 Referent Adjusted for age; P for trend 
= 0.03
3,000–3,499 1.37 (0.34–5.47)
3,500–3,999 2.18 (0.58–8.21)
≥ 4,000 5.03 (1.13–22.47)
[28] 2005 LCohort 311 16,011 USA <3,040 Referent Adjusted for year of birth
3,040–3,310 1.4 (1.0–2.1)
3,320–3,550 1.0 (0.6–1.5)
3,560–3,830 1.3 (0.9–1.9)
≥ 3,840 1.5 (1.0–2.2)
[29]a 2005 LCohort 367 5,346 Sweden <50 years
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<3,000 Referent
3,000–3,499 1.81 (0.77–4.26)
3,500–3,999 2.66 (1.09–6.46)
≥ 4,000 4.00 (1.49–10.72)
≥ 50 years
<3,000 Referent
3,000–3,499 0.86 (0.62–1.19)
3,500–3,999 1.06 (1.20–3.34)
≥ 4,000 0.91 (0.57–1.46)
[40] 2006 Cohort 97 5,847 USA <3,000 0.98 (0.61–1.60) Adjusted for age
3,000–3,499 Referent
≥ 3,500 1.09 (0.66–1.80)
[30] 2006 Cohort 3,140 91,601 USA Premenopause Adjusted for age: P for trend 
= 0.019
<2,495 0.69 (0.50–0.94)
2,495–3,130 0.79 (0.64–0.97)
3,131–3,810 0.76 (0.63–0.93)
>3,810 Referent
Postmenopause: Adjusted for age: P for trend 
= 0.99
<2,495 1.04 (0.88–1.23)
2,495–3,130 1.00 (0.87–1.14)
3,131–3,855 1.05 (0.93–1.20)
>3,855 Referent
[31] 2006 Cohort 209 1,024 USA <2,500 0.9 (0.5–1.6) Hazard ratio; adjusted for 
age at diagnosis, diagnosis 
year, stage at diagnosis, and 
birth order, with exception of 
birth order, which is 
adjusted for maternal age
2,500–3,999 Referent
≥ 4,000 1.8 (1.0–3.1)
(P trend = 0.1)
[41] 2007 Cohort 657 38,566 Sweden <2,500 0.65 (0.43–0.99) Adjusted for adult body 
mass index
2,500–3,000 1.04 (0.86–1.25)
>3,000 Referent
Cohort, cohort study; LCC, case-control study with linkage with population and cancer registry data; LCohort, cohort study with linkage with 
population and cancer registry data; LTCCS, twin case-control study by using linkage with birth and cancer registry data; NCC, nested case-
control study in cohort; PCC, population-based case-control study. aThe numbers of cases and controls were not shown in the original article.
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Table 3
Studies assessing the association of birth order and the risk of breast cancer
Type of 
study
Ref. Year Design Cases Controls
(or cohort)
Country/
place of study
Birth
order
OR (95% CI) Comments
Case-
control 
studies
[51] 1967 LCC-D 229 229 USA 1 - The authors measured the 
mean value of birth weight 
instead of providing ORs (95% 
CIs). The mean difference 
between cases and matched 
controls was not significant (P 
> 0.2). They provided the 
frequency of each case and 
control in the tables and we 
calculated crude ORs
2
3
4
5
6
≥ 7
[50]a 1980 MCC 4339 12,760 USA, Japan, 
Slovenia, 
Athens, Taipei
1 Referent The risks (point estimates) only 
by birth order were shown in 
the figure in the original article.
20 . 9 3
31 . 0 8
40 . 9 9
51 . 0 5
61 . 0 7
71 . 1 8
≥ 81 . 0 2
[42] 1988 PCC 153 461 USA 1 Referent P for trend = 0.16
2 0.92 (0.55–1.54)
3 0.98 (0.58–1.72)
4 0.69 (0.36–1.32)
≥ 5 1.03 (0.60–1.79)
[46] 1991 MCC 927 2,616 USA/Wales/
Japan
All ages Adjusted for age, study center, 
parity, age at first birth, age at 
menarche, height, body mass 
index, maternal age at birth, and 
menopausal status
1 Referent
2 0.91 (0.73–1.02)
3 1.11 (0.87–1.27)
≥ 4 1.09 (0.81–1.18)
Premenopa
usal
1 Referent
≥ 2 0.76 (0.60–0.96)
[12] 1992 LCC 458 1,197 Sweden 1 Referent Adjusted for age and birth date
≥ 2 1.00 (0.76–1.32)Available online http://breast-cancer-research.com/content/10/1/R8
Page 19 of 34
(page number not for citation purposes)
[47] 1994 PCC 2,414 9,138 USA 1 Referent Adjusted for age at first birth 
and number of children
2 0.90 (0.78–1.03)
3 0.98 (0.84–1.14)
4 0.86 (0.73–1.02)
5 0.93 (0.78–1.11)
6 1.02 (0.84–1.23)
7 0.91 (0.73–1.14)
≥ 8 0.88 (0.75–1.04)
[14] 1996 PCC 1,129 1,393 USA 1 Referent Adjusted for age, menopausal 
status, and maternal smoking; 
P for trend = 0.06 among both 
groups
2 1.0 (0.7–1.4)
≥ 3 0.8 (0.6–1.1)
[32] 1997 NCC 1,068 2,727 Sweden 1 Referent Adjusted for maternal age, 
socioeconomic status, parity, 
and preeclampsia or eclampsia, 
neonatal jaundice, severe 
prematurity, and twinship
2 1.01 (0.83–1.22)
≥ 3 1.01 (0.81–1.26)
[15] 2000 LCC 481 2,863 USA 1 1.07 (0.84–1.35) Crude ORs
2–3 Referent
4–5 1.06 (0.81–1.38)
≥ 6 1.50 (1.06–2.13)
[35] 2002 PCC 1,555 1,539 USA 1 Referent Adjusted for age and residential 
regions (states)
2 1.07 (0.88–1.30)
3 1.07 (0.85–1.35)
4 1.01 (0.77–1.31)
5 0.66 (0.48–0.92)
≥ 6 0.81 (0.62–1.08)
[18] 2003 LCC 881 3,423 Denmark 1 Referent Adjusted for mother's marital 
status, maternal age, and birth 
order
≥ 2 1.01 (0.83–1.12)
[36] 2004 PCC 854 785 USA All subjects Adjusted for age, race and 
sampling fractions, body mass 
index, hosehold income, 
maternal age
1 Referent
2–4 0.9 (0.7–1.1)
≥ 5 1.0 (0.8–1.3)
Born ≥ 
1948
1 Referent
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2–4 0.9 (0.6–1.4)
≥ 5 0.6 (0.3–1.3)
[48]a 2005 MCC 24 34 Nigeria ≤ 3 Referent Crude ORs
≥ 4 1.50 (0.25–8.98)
[20] 2005 PCC 1642 1,713 Poland 1 Referent Adjusted for age, education, 
age at menarche, menopausal 
status and age at menopause, 
age at first full-term pregnancy, 
number of full-term 
pregnancies, family history of 
breast cancer among first-
degree relatives, 
mammography screening, and 
current body mass index
2 1.07 (0.91–1.24)
3–5 0.99 (0.85–1.15)
≥ 6 0.81 (0.61–1.06)
P for trend = 0.81
[37] 2006 PCC 1,166 2,105 USA 1 Referent Adjusted for age (years), 
education (years), race, body 
mass index, history of breast 
benign disease, family history of 
breast cancer, lactation 
(months), age at menarche 
(years), age at first full-term 
pregnancy (years), age at 
menopause (years), parity
≥ 2 1.27 (0.88–1.85)
Cohort 
studies
[31] 2006 Cohort 209 1,024 USA 1 Referent Hazard ratio for breast cancer 
mortality: adjusted for age at 
diagnosis, diagnosis year, 
stage at diagnosis, and birth 
order, with exception of birth 
order, which is adjusted for 
maternal age
2 0.2 (0.2–0.3)
≥ 3 0.2 (0.2–0.3)
P for trend < 0.01
[49]a 2001 Cohort - - Sweden Continuous
scale
1.05 (1.01–1.10)
aWe did not include these studies in the meta-analysis because they employed different categories or a continuous scale, or they did not provide 
the numbers of cases and controls in the original article. Cohort, cohort study; LCC, case-control study with linkage with population and cancer 
registry data; LCC-D, case-control study with linkage with population and cancer death certification data; MCC, multicenter case-control study; 
NCC, nested case-control study in cohort; PCC, population-based case-control study.
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Table 4
Studies assessing the association of maternal age with risk for breast cancer
Ref. Year Design Cases Controls
(or cohort)
Country/
place of study
Maternal
age (years)
OR (95% CI) Comments
Case-
control 
studies
[51] 1967 LCC-D 229 229 USA ≤ 19 Mean maternal age among 
cases was higher than that 
among controls (P < 0.005). 
The frequency of each case and 
control were shown in the tables 
provided and we calculated 
crude ORs
20–24
25–29
30–34
35–39
≥ 40
[61]a 1974 PCC 308 308 USA Matched analysis; the mean 
maternal age was 27.3 years 
among cases and 26.3 years 
among controls (P < 0.01)
[50]b 1980 MCC 4339 12760 USA, Japan, 
Slovenia, 
Athens, Taipei
≤ 19 Referent Authors showed point estimates 
of ORs without 95% CIs. The 
frequencies for each case and 
control were given in the tables 
provided and we calculated 
crude ORs
20–24 1.05
25–29 1.22
30–34 1.19
35–39 1.31
≥ 40 1.18
[53]a 1984 MCC 1,176 1,176 England ≤ 20 Referent Adjusted for age, social class, 
family history of breast cancer, 
age at first-term birth, past 
history of benign breast disease, 
age at menarche, menopausal 
status, cigarette smoking, and 
oral contraceptive use
21–25 1.41 (0.92–2.18)
26–30 1.19 (0.78–1.81)
31–35 1.29 (0.83–1.98)
≥ 36 1.19 (0.68–1.67)
[42]a 1988 PCC 153 461 USA All women Matched analysis
15–22 1.18 (0.71–1.97)
23–26 Referent
27–30 1.22 (0.71–2.10)
31–46 1.66 (0.99–2.78)
P for trend = 
0.67
Younger 
women
15–23 1.39 (0.65–2.95)
24–28 ReferentBreast Cancer Research    Vol 10 No 1    Park et al.
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29–46 2.21 (1.02–4.80)
P for trend = 
0.08
[52]a 1989 PCC 801 1,573 USA Continuous 1.24 (1.09–1.41) Crude OR
[54] 1990 PCC 2,291 3,144 USA ≤ 19 Referent Adjusted for age and parity, age 
at first pregnancy, total duration 
of breast feeding, race, age at 
menarche, menopausal status, 
body mass index, family history 
of breast cancer, and breast 
biopsy
20–24 0.95 (0.77–1.16)
25–29 1.13 (0.92–1.38)
30–34 1.16 (0.93–1.45)
35–39 1.46 (1.10–1.93)
≥ 40 1.20 (0.79–1.83)
[55] 1991 PCC 1761 1,116,55
3 person-
years
USA ≤ 19 Referent Crude ORs
20–24 1.02 (0.82–1.46)
25–29 1.12 (1.04–1.38)
30–34 1.16 (0.93–1.44)
35–39 1.17 (0.92–1.48)
≥ 40 1.08 (0.80–1.46)
[46]a 1991 MCC 927 2616 USA, Wales, 
Japan
Each 5-yrs 1.06 (1.01–1.10) Adjusted for age, study center, 
parity, age at first birth, age at 
menarche, height, BMI, maternal 
age at birth, and menopausal 
status
[12]b 1992 LCC 458 1,197 Sweden Each 5-year 
band
1.01 (0.92–1.12) Adjusted for age and birth date. 
The authors estimated breast 
cancer risk according to each 5-
year band of maternal age. The 
frequency of each case and 
control were given in the tables 
provided and we calculated 
crude ORs
[47] 1994 PCC 2,412 9,138 USA ≤ 19 Referent Adjusted for age at first birth 
and number of children
20–24 1.05 (0.85–1.30)
25–29 1.10 (0.89–1.37)
30–34 1.10 (0.88–1.37)
35–39 1.09 (0.87–1.37)
≥ 40 0.99 (0.76–1.28)
[14] 1996 PCC 1,934 2,161 USA ≤ 24 Referent Adjusted for age, menopausal 
status, and maternal smoking
25–29 1.0 (0.8–1.2)
30–34 0.9 (0.6–1.1)
≥ 35 1.0 (0.7–1.5)
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[57] 1997 PCC 1,253 1,121 USA ≤ 19 Referent Adjusted for age, menopausal 
status, age at menarche, parity, 
age at first birth, body mass 
index, past history of benign 
breast disease, and recent 
alcohol intake
20–24 0.84 (0.62–1.14)
25–29 1.02 (0.76–1.37)
30–34 0.93 (0.68–1.28)
35–39 1.16 (0.82–1.65)
≥ 40 0.92 (0.62–1.37)
[58] 1997 PCC 2,106 1,926 USA ≤ 19 Referent Adjusted for age, study site, 
family history of breast cancer, 
breast biopsy, a combination 
variable including number of full-
term births and age at first full-
term pregnancy, age at 
menarche, menopausal status, 
body mass index, average 
lifetime alcohol consumption, 
and the number of 
mammograms
20–24 0.96 (0.7–1.2)
25–29 0.96 (0.7–1.2)
30–34 0.91 (0.7–1.2)
≥ 35 0.93 (0.7–1.3)
[32]a 1997 NCC 1,067 2,725 Sweden Each 5-year 
band
1.06 (0.99–1.14) Adjusted for maternal age, 
socioeconomic status, parity, 
and pre-eclampsia or eclampsia, 
neonatal jaundice, severe 
prematurity, and twinship
[15] 2000 LCC 481 2863 USA ≤ 19 1.19 (0.83–1.72) Crude ORs
20–24 Referent
25–29 1.26 (0.97–1.64)
30–34 1.38 (1.04–1.84)
≥ 35 1.70 (1.23–2.35)
[35] 2002 PCC 1,555 1,539 USA ≤ 19 1.02 (0.75–1.39) Adjusted for age and state
20–24 0.98 (0.81–1.18)
25–29 Referent
30–34 1.15 (0.93–1.42)
35–39 1.22 (0.94–1.58)
≥ 40 1.27 (0.90–1.69)
[18] 2003 LCC 881 3,423 Denmark ≤ 24 Referent Adjusted for mother's marital 
status, maternal age, and birth 
order
25–29 1.08 (0.88–1.32)
≥ 30 1.11 (0.90–1.36)
[36]a 2004 PCC 854 785 USA ≤ 18 1.8 (0.9–3.4)
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19–22 Referent Adjusted for age, race and 
sampling fractions; tertiles are 
race specific with cutpoints 
derived from controls
23–27 3.0 (1.8–5.0)
≥ 28 2.5 (1.6–4.0)
[56] 2005 MCC 1,060 1,060 Korea ≤ 24 Referent Adjusted for age, family history 
of breast cancer in first-or 
second-degree relatives, 
menopausal status, and lifetime 
estrogen exposure duration
25–29 1.2 (0.93–1.47)
30–34 1.4 (1.12–1.83)
≥ 35 1.1 (0.83–1.37)
[20] 2006 PCC 1,642 1,713 Poland ≤ 19 Referent Adjusted for: age, education, 
age at menarche, menopausal 
status and age at menopause, 
age at first full-term pregnancy, 
number of full-term pregnancies, 
family history of breast cancer 
among first-degree relatives, 
mammography screening, and 
current body mass index
20–24 1.02 (0.75–1.39)
25–29 1.07 (0.79–1.46)
35–39 1.16 (0.84–1.60)
≥ 35 0.91 (0.66–1.27)
P for trend = 
0.76
[37]a 2006 PCC 1,166 2,105 USA ≤ 24 Referent Adjusted for: age, education, 
race, body mass index, history of 
breast benign disease, family 
history of breast cancer, 
lactation, age at menarche, age 
at first full-term pregnancy, age 
at menopause, and parity
25–35 0.87 (0.67–1.13)
>35 0.87 (0.59–1.27)
Cohort 
studies
[59] 1995 Cohort 149 75,237 USA ≤ 24 Referent Adjusted for age, education, 
menopausal status, parity, body 
mass index, height, smoking, 
and alcohol drinking
25–29 1.3 (0.8–2.0)
30–34 1.4 (0.9–2.1)
≥ 35 1.2 (0.7–2.0)
[60] 1995 Cohort 1,967 384,769 Sweden ≤ 19 Referent Breast cancer mortality; 
adjusted for age
20–24 0.99 (0.82–1.21)
25–29 1.00 (0.82–1.22)
30–34 0.97 (0.79–1.18)
35–39 1.04 (0.84–1.29)
40–44 0.93 (0.71–1.21)
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≥ 45 1.39 (0.91–2.13)
[49]a 2001 Cohort Sweden Continuous 
scale
1.07 (0.91–1.27) Adjusted for spouse age, year of 
diagnosis, and birth order
[38]a 2001 Cohort 177 3,447 Filand Continuous 
scale
-N o  a s s o c i a t i o n
[31] 2006 Cohort 249 1,024 USA ≤ 24 Referent Hazard ratio; adjusted for age at 
diagnosis, diagnosis year, stage 
at diagnosis, and birth order, 
with exception of birth order, 
which is adjusted for maternal 
age
25–29 1.2 (0.9–1.7)
30–34 1.4 (0.9–1.9)
≥ 35 1.7 (1.1–2.8)
P for trend = 
0.03
aWe did not include these studies in the meta-analysis because they employed different categories or a continuous scale, or they did not provide 
the numbers of cases and controls in the original articlebWe included this study in the meta-analysis because we calculated the crude OR using 
the number of subjects represented the original article. Cohort, cohort study; LCC, case-control study with linkage with population and cancer 
registry data; LCC-D, case-control study with linkage with population and cancer death certification data; MCC, multicenter case-control study; 
NCC, nested case-control study in cohort; PCC, population-based case-control study.
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Table 5
Table 5 Studies assessing the association of premature birth and the risk of breast cancer
Type of 
study
Author Year Design Cases Controls
(or cohort)
Country/
place of study
Gestational
age (weeks)
OR (95% CI) Comments
Case-
control 
studies
[42]a 1988 PCC 153 461 USA 25–32 1.16 (0.50–1.54) Matched analysis
33–40 Referent
[13]b 1996 NCC 571 1,525 USA Categorical Adjusted for age
40 Referent
38–39 0.76 (0.44–1.32)
36–37 0.96 (0.59–1.56)
Binomial
≥ 37 Referent
≤ 36 0.82 (0.37–1.82)
[14] 1996 PCC 1123 1371 USA Nonpreterm Referent Adjusted for age, 
menopausal status, and 
maternal smoking
Preterm 1.1 (0.5–2.1)
[32]a 1997 NCC 1,010 2,625 Sweden ≥ 33 Referent Adjusted for maternal 
age, matermal 
socioeconomic status, 
maternal parity, 
maternal pre-eclampsia 
or eclampsia, neonatal 
jaundice, severe 
prematurity, twin, and 
birth weight
≤ 32 3.96 (1.46–10.81)
[33]b 1998 PCC 502 433 USA ≥ 43 1.5 (0.8–2.6) Crude ORs
37–42 Referent
≤ 36 0.9 (0.5–1.8)
[15]a,b 2000 LCC 480 2,854 USA ≥ 37 Referent Crude ORs
33–36 1.34 (0.85–2.13)
≤ 32 0.55 (0.19–1.57)
[34]a,b 2001 LCC 87 87 Sweden ≥ 40 8.4 (1.3–54.4) Matched analysis by 
conditional logistic 
regression
37–40 3.4 (0.7–17.0)
33–36 3.5 (0.7–17.5)
≤ 32 Referent
[25]a 2003 LCohort 127 (1,483) Sweden ≥ 33 1.08 (0.64–1.70) Standardized incidence 
ratio (expected/
observed)
≤ 32 0.92 (0.57–1.41)
[45]a,b 2004 LCC 2,471 9,801 USA ≥ 37 Referent Adjusted for age and 
maternal age at first 
birth
32–36 0.91 (0.72–1.13)
≤ 31 1.43 (0.90–2.28)Available online http://breast-cancer-research.com/content/10/1/R8
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[20]b 2005 PCC 1,424 1,457 Poland ≥ 37 Referent Adjusted for age, 
education, age at 
menarche, menopausal 
status and age at 
menopause, age at first 
full-term pregnancy, 
number of full-term 
pregnancies, family 
history of breast cancer 
among first-degree 
relatives, mammography 
screening, and current 
body mass index
≤ 36 1.01 (0.75–1.32)
Cohort 
studies
[62]c 2000 LCohort 12 273 Sweden 35 0.2 (0.01–1.3) Standardized incidence 
ratio
33–34 0.7 (0.1–2.0)
31–32 2.3 (0.7–5.3)
<31 6.7 (1.4–19.5)
[16]c 2001 LTCCS 2,265 9,060 Sweden 33–36 Referent Crude ORs
37–38 1.8 (0.83–4.0)
40–44 2.0 (0.88–4.6)
[29]c 2005 LCohort 367 5,346 Sweden 1 week increase <50 years
0.94 (0.83–1.07)
[40]c 2006 Cohort 97 5,847 USA <39 0.77 (0.42–1.4) Adjusted for age
39 1.38 (0.78–2.4)
40 Referent
41+ 1.33 (0.67–2.6)
[31]b 2006 Cohort 249 1024 USA ≥ 43 0.7 (0.2–2.7) Adjusted for: age at 
diagnosis, diagnosis 
year, stage at diagnosis, 
and birth order, with 
exception of birth order, 
which is adjusted for 
maternal age
37–42 Referent
<37 1.4 (0.7–2.9)
P for trend = 0.3
Cohort, cohort study; LCC, case-control study with linkage with population and cancer registry data; LTCCS, twin case-control study by using 
linkage with birth and cancer registry data; NCC, nested case-control study in cohort; PCC, population-based case-control study. aWe included 
this study in the meta-analysis with categories of ≥33 versus ≤32 months (reference). bWe included this study in the meta-analysis with categories 
of ≥37 versus ≤36 months (reference). cWe did not include these studies in the meta-analysis because they employed different categories or a 
continuous scale, or they did not provide the numbers of cases and controls in the report.
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Table 6
Studies assessing the association of twinship with risk for breast cancer
Type of 
study
Ref. Year Design Cases Controls
(or cohort)
Country/
place of study
Category OR (95% CI) Comments
Case-
control 
studies
[63]a 1992 MCC 870 2,741S UK, USA Singleton Referent Adjusted for age, study 
center, parity, age at first 
birth, age at menarche, 
height, body mass index, 
maternal age at birth, 
birth order, and 
menopausal status
Twinship 1.40 (0.77–2.55)
Singleton Referent
Monozygote twin 1.30 (0.58–2.92)
Dizygote twin 1.54 (0.64–3.71)
[14] 1996 PCC 1,134 1,380 USA Age 21–45 Adjusted for age, 
menopausal status, and 
maternal smoking
Singleton Referent
Twinship 0.6 (0.3–1.3)
Age 50–64
Singleton Referent
Twinship 0.9 (0.4–2.2)
[58]a 1997 PCC 2,150 1,961 USA Singleton Referent Adjusted for age, study 
site, family history of 
breast cancer, breast 
biopsy, a combination 
variable including 
number of full-term 
births and age at first 
full-term pregnancy, age 
at menarche, 
menopausal status, 
body mass index, 
average lifetime alcohol 
consumption, and the 
number of 
mammograms
Twinship 1.6 (1.0–2.7)
Singleton Referent
Monozygote twin 1.39 (0.7–2.6)
Dizygote twin 2.06 (1.0–4.5)
[32] 1997 NCC 1,068 2,727 Sweden Singleton Referent Adjusted for maternal 
age, matermal 
socioeconomic status, 
maternal parity, maternal 
pre-eclampsia or 
eclampsia, neonatal 
jaundice, severe 
prematurity, twin, and 
birth weight
Twinship 1.3 (0.8–2.1)
Singleton Referent
Monozygote twin 0.7 (0.2–2.2)
Dizygote twin 1.5 (0.8–2.7)
[15] 2000 LCC 481 2,863 USA Singleton Referent Crude ORs
Twinship 1.04 (0.51–2.11)
[43] 2001 LCC 319 768 USA Singleton Referent Crude ORsAvailable online http://breast-cancer-research.com/content/10/1/R8
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Twinship 1.6 (0.2–10.1)
[45] 2004 LCC 2,522 10,052 USA Singleton Referent Adjusted for age and 
maternal age at first 
birth
Twinship 1.77 (1.05–2.97)
[20] 2005 PCC 2,338 2,476 Poland Singleton Referent Adjusted for age, 
education, age at 
menarche, menopausal 
status and age at 
menopause, age at first 
full-term pregnancy, 
number of full-term 
pregnancy, family history 
of breast cancer among 
first-degree relatives, 
mammography 
screening, and current 
body mass index
Twinship 0.76 (0.49–1.16)
Singleton Referent
Monozygote twin 0.90 (0.53–1.52)
Dizygote twin 0.58 (0.23–1.47)
Cohort 
studies
[64] 1980 LTCohort 270 (16,922) Denmark Twinship 1.1 (1.0–1.2) Observed/expected 
ratio (95% CI)
[65] 1995 LTCohort 740 (25,541) Sweden Twinship 1.1 (1.0–1.1) Observed/expected 
ratio (95% CI)
Monozygote twin 1.0 (0.9–1.2)
Dizygote twin 1.1 (1.0–1.2)
[67] 1999 LTCohort 245 (13,176) Finland Twinship 0.91 (0.81–1.00) Observed/expected 
ratio (95% CI)
Monozygote twin 0.76 (0.59–0.97)
Dizygote twin 0.98 (0.84–1.10)
[66] 2000 Cohort 1,230 (29,197) USA Singleton Referent Adjusted for age, 
education, family history 
of breast cancer, age at 
menarche, age at first 
birth, height, current 
body mass index, body 
mass index at age 18, 
waist:hip ratio, alcohol 
drinking, and hormone 
replacement therapy
Twinship 1.72 (1.22–2.42)
Singleton Referent
Monozygote twin 1.04 (0.43–2.5)
Dizygote twin 1.77 (1.16–2.7)
[31] 2006 Cohort 249 1,024 USA Singleton Referent Adjusted for age at 
diagnosis, diagnosis 
year, stage at diagnosis, 
and birth order, with 
exception of birth order, 
which is adjusted for 
maternal age
Twinship 2.5 (1.0–6.2)
aAuthors used the female twins as the proxy of the monozygote twin and the female twin with male twin as the proxy of the dizygote twin. Cohort, 
cohort study; LCC, case-control study with linkage with population and cancer registry data; LTCohort, twin cohort study by using linkage with 
birth and cancer registry data; MCC, multicenter case-control study; NCC, nested case-control study in cohort; PCC, population-based case-
control study.
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Table 7
Studies assessing the association of maternal or paternal smoking and the risk of breast cancer
Type of 
study
Ref. Year Design Cases Controls
(or cohort)
Country/
place of study
Smoking status OR (95% CI) Comments
Case-
control 
studies
[69] 1996 PCC 53 470 USA Maternal 
smoking
Crude ORs
No Referent
Yes 0.9 (0.4–2.1)
Paternal 
smoking
No Referent
Yes 1.3 (0.9–1.7)
[14] 1996 PCC 1,086 1,321 USA Maternal 
smoking
Adjusted for age, 
menopausal status, and 
maternal smoking; OR (95% 
CI) for maternal smoking 
among early-onset breast 
cancer patients (≤ 30 years 
old) was 1.9 (1.0–3.4)
Age 21–45 
years
No Referent
Yes 1.1 (0.9–1.3)
Age 50–64 
years
No Referent
Yes 1.3 (0.9–2.1)
[58] 1997 PCC 522 484 USA Maternal 
smoking
Adjusted for age, study site, 
family history of breast 
cancer, breast biopsy, a 
combination variable 
including number of full-term 
births and age at first full-
term pregnancy, age at 
menarche, menopausal 
status, body mass index, 
average lifetime alcohol 
consumption, and the 
number of mammograms
No Referent
Yes 1.1 (0.8–1.4)
[33] 1998 PCC 507 433 USA Maternal 
smoking
Crude ORs
No Referent
Yes 1.1 (0.9–1.5)
[43] 2001 LCC 319 768 USA Maternal 
smoking
Adjusted for attained age
No Referent
Yes 2.7 (1.1–6.3)
[35]a 2002 PCC 1,535 1,534 USA Smoking Adjusted for age and 
residential regions (states)
No Referent
Paternal 
smoking
1.00 (0.88–1.13)Available online http://breast-cancer-research.com/content/10/1/R8
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Maternal/
parental 
smoking
1.10 (0.84–1.42)
[20] 2005 PCC 2380 2,497 Poland Maternal 
smoking
Unadjusted; recalculated
No Referent
Yes (any 
exposure)
1.19 (0.97–1.47)
Paternal 
smoking
No Referent
Yes (any 
exposure)
0.90 (0.77–1.05)
Cohort 
studies
[31] 2006 Cohort 249 1,024 USA Maternal 
smoking
Referent Adjusted for age at 
diagnosis, diagnosis year, 
stage at diagnosis, and birth 
order, with exception of birth 
order, which is adjusted for 
maternal age Crude relative 
rates
No 0.8 (0.5–1.1)
Yes (any 
exposure)
[68] 2005 Cohort 42 (3,989) USA Maternal 
smoking
No Referent
Yes (any 
exposure)
0.49 (0.29–1.03)
≤ 15 
cigarettes a 
day
0.33 (0.12–0.94)
>15 0.68 (0.26–1.73)
aTitus-Ernstoff and coworkers [35] classified three categories: nonparental smoking, either paternal or maternal smoking only or both parents 
smoking during pregnancy. Thus, in this study, the maternal or both parents smoking versus nonparental smoking can be regarded as maternal 
smoking versus no maternal smoking. Cohort, cohort study; LCC, case-control study by linkage with population data and cancer registry data; 
PCC, population-based case-control study.
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